Biological, as opposed to classic antipsoriatic drug or apremilast, treatment mitigates the risk of death and cardiovascular disease in psoriasis
Khalaf Kridin, Katja Bieber, Artem Vorobyev, Eva Lotta Moderegger, Henning Olbrich, Marlene A. Ludwig, Bernard Gershater, Gema Hernandez, Henner Zirpel, Diamant Thaci, Ralf J. Ludwig
Research output: Contribution to journal › Article › peer-review
Fingerprint
Dive into the research topics of 'Biological, as opposed to classic antipsoriatic drug or apremilast, treatment mitigates the risk of death and cardiovascular disease in psoriasis'. Together they form a unique fingerprint.